BACKGROUND INFORMATION ON THE PROCEDURE 
1. Submission of the dossier 
The applicant Sanofi Pasteur MSD, SNC submitted on 05 December 2005 an application for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Gardasil,  through 
the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation 
(EC) No 726/2004. 
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
The application submitted is a complete dossier: 
composed of administrative information, complete quality data, non-clinical and clinical data 
literature 
based  on 
substituting/supporting certain test(s) or study(ies). 
and/or  bibliographic 
applicants’  own 
studies 
tests 
and 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 21 January 2004. The Scientific 
Advice pertained to clinical aspects of the dossier. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Bengt Ljungberg 
Co-Rapporteur: 
Eric Abadie 
2. Steps taken for the assessment of the product 
•  The application was received by the EMEA on 5 December 2005. 
•  The procedure started on 28 December 2005.  
•  The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  17 
March  2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 23 March 2006.   
•  The  Vaccine  Working  Party  during  its  meeting  of  28-30  March  2006  adopted  a  VWP 
Report to be transmitted to the CHMP for endorsement. 
•  The  Biologics  Working  Party  during  its  meeting  of  19-20  April  2006  adopted  a  BWP 
Report to be transmitted to the CHMP for endorsement. 
•  During  the  meeting  on  24-27  April  2006  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to 
the applicant on 27 April 2006. 
•  The applicant submitted the responses to the CHMP consolidated List of Questions on 18 
May 2006. 
1/2 
©EMEA 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
•  The Rapporteurs circulated the D150 Joint Assessment Report on the applicant’s responses 
to the List of Questions to all CHMP members on 30 June 2006. 
•  The Vaccine Working Party during its meeting of 4-6 July 2006 adopted a VWP Report to 
be transmitted to the CHMP for endorsement. 
•  The  Biologics  Working  Party  during  its  meeting  of  17-19  July  2006  adopted  a  BWP 
Report to be transmitted to the CHMP for endorsement. 
•  The Rapporteurs circulated the D180 Joint Assessment Report on the applicant’s responses 
to the List of Questions to all CHMP members on 20 July 2006. 
•  During  the  meeting  on  24-27  July  2006  the  CHMP,  in  the  light  of  the  overall  data 
submitted and the scientific discussion within the Committee, issued a positive opinion for 
granting a Marketing Authorisation to Gardasil on 27 July 2006. The applicant provided 
the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 27 
July 2006. 
•  The CHMP opinions were forwarded, in all official languages of the European Union, to 
the European Commission, which adopted the corresponding Decisions on 20 September 
2006. 
2/2 
©EMEA 2006 
 
 
 
 
 
 
 
